

• •



2015 .

2 ，		， ·	· ()， ·
2 ，	， ·	， ()， ·)， - ()， ·	·
2 ，	， ； ·	， · ·	； ·

10

M32
M32.0
M32.1 +
M32.8
M32.9

() -

；

8-9 ，

14-25 ；

15

4,5:1.

10-19 - 4,4 31,1 1 9 1,0-6,2
0,4-0,9 100 . .

HLA-DR2 HLA-DR3 1:40, - 1:250. 2-3
1, 8, DR3 10-

(C1q, C2, 4), Fc RII - Fc RIIIA-
(IgG -)

() 1, 3, 6 - ,

() ,

()

• (III):
 - ;
 - () ,
 /) ,
 () , - () ,
 /) ;
 - 45 / ;
 - ;
 - ;
 3, 4).

« »:

• (II)
 - ;
 - ;
 - ;
 - ;
 - ;
 - 25-45 / ;
 - ,

• (I):
 - ;
 - ;
 - ;

• :
 -

- SLEDAI (The Systemic Lupus Erythematosus Disease Activity Index);
- SLAM (The Systemic Lupus Activity Measure);
- BILAG (The British Isles Lupus assessment Group Index);
- ECLAM (The European Consensus Lupus Activity Measured) (.2).
 SLEDAI BILAG.

(SLICC/ACR Damage Inde).

2.
**ECLAM (European
Consensus Lupus Activity Measurement)**

1.	(× 0,5)
	37,5 ,
2.	(× 0,5)
	(, , -)
)
3 .	-
	-
	- , .
	, , ,
	, , ,
3 .	- (× 1 , ; - + 1)
4.	(× 2 , / ,)
5.	(× 1 ,) ,
6.	(× 2)
7.	(× 1)
	,)
	,

	-
8.	(× 2)
/	,
	,
	,
	-
	,
9 .	(× 0,5)
	0,5 /
	,
	-
9 .	(× 2 ,)
)
10.	(× 1)
	-)
	-
	3500, 1500
	100 000
11.	
> 25 /	
12.	(× 1)
3	
50	
12 .	(× 1)
	(4)

1 – 10, 2 . - ,

> 10, 10. <6 > 6.

20%

(), , ,

,

80-95%

« »

80%

40% -

(),

-

,

, ;

-

-

-

-

.

-

-

-

,

-

,

« »,

;

-

30%

-

-

-

()

90%

10-15%

30-40%

30-50%

10-30%

(;)

- ;

(),

52-89%

(.).

1-4

70-75 %

2

1/3 -

6

(.3).

3.

()

		-
I	,	
II	() ()	
II) ()	< 1 / 5-15 /
III	() , 50%)	< 2 / 5-15 /

IV	50%) III (> 2 / > 20 /
V	()	> 3,5 /
VI	(,)	

30-40% . , ,
 () ; - . ,
 . , , -
 , () (- .

30-50% .
 - ; ;
 () ;
 (, ,), - ,
 (; , , , , -).

- .
 .
 , 24 . , ,
 () , ,
 - - , ,
 , -

).
 - 3-5%
 (44%)
 28% - 25%,
 - 3%.
 () 95% ;
 40-70% ;
 ; *Sm-* - 20-50% ;
 (*Ro-*) ; (*La-*)
), ; 60-80%
 ;
) (50-60% 2- *I*,
 (CH50)
 (3, 4)

	<p style="text-align: center;">:</p> <p>1) (IgM IgG);</p> <p>2) ;</p> <p>3)</p> <p>6 ,</p>
<p>11.</p> <p>()</p>	

4-

3-

- 78-96%, - 89-96%.

:

(, - , , .),

(,), (, ,), -

.), (

),

IV ,

6 ,

TH-8.

D

()

•

(2)

•

(1,5) / / (70-80 /);
8-10
(0,2-0,3 /),

1

•

- 0,7—1,0 / / ;
(0,2-0,3 / - 6-8

•

- 0,3—0,5 / / ;
0,2-0,3 / - 4-6 ,

- (2)

1000 /) 3-5 10—30 / / (

()

:

-

;

-

;

-

;

-

;

-

;

-

() (2)

/ 2 per os

1

() , 1,0—2,5 / ,
0,5 (0,75—1,0)

(2)

(, 1,0—3,0 /
) (4,5—5,0 . 109/).

(2)

2,0—5,0 /

per os

(V),

(2)

600 / 2
450 / 2

2

2

• , : ;
 • ;
 •

() (2)
 7,5-10,0 / 2 per os 6
 « »

() (1)
 100-400 / (5,0 /)
 125-250 / (4,0 /)

(2)
 0,2 /
 , (, ,
), - 0,4-2,0 / ,

(**CD20** - -) (2)

CD20+ - :
 4 - 375 / 2 1
 14 . 750 / 2

(2) - 20 ,
 2 . 12-14 ,

6-12 :
 (2) - ,
 2-3 . - 12 5 /

■ (2) - 1, ,
 (, , ,
), ,

■ :

： () 2 ，
/ / . ， 14 ，
/ ， 2- 3 / / 3- ，
， (，)
() .
(2) -

；

Xa.

-II -

: 65-85

() .

(-)

),

3-4 /

0.2 - 0.4 - / .

1 - 1.5 - / .

(2) .

2,0-3,0.

()

■ , - ;
 ■ . , ;
 - , , (« », 7
 2009 . 415 ,
 26 2011 . 1644 , 23 2010 .
 541).

, . . .

-
-

-42

-14

() , -
 , :
 — ;
 — ;
 • , :
 — - + 5
 / / ,
 • — , « »:
 — ;
 — ;
 — , (), , ;
 — , (— ;)
 — , , ;
 — , (, -).
 • — - + 15 / / ()
 — 14-21 ;
 — 15 / / 14-21 ;
 — 50-100 / / 14 .
 • :
 — 5-10 / / 8 ,

• (,) — 1 2 :
 — , , , , —

• (,) — 1 2 :
 — , , 5-7 :
 —

• (Ig A, M, G; , ,
 [2-], I,) — 1 3
 , , .

• — 1 2 .
 • 1 3 .
 • , , — 1 6 .
 • 2
 — .

• , -
 • - — 1 14 .
 • — 1 14 (, ,
 , ,).

• 1,5 10⁹ /
 — ;
 — 5 10 / 3-5 , ()
 , .

• :
 — 10 / 3-5 , () 5-
 , ;
 — (50-100 /
) ;
 — , ;
 — , .

• , :
 — ;
 — () (, , ,
 ,);
 — + 15 / / , 15
 / / , 50-100 / ;
 — ;
 — , .

7. Gurevitz S.L., Snyder J.A., Wessel E.K. et al. Systemic lupus erythematosus: a review of the disease and treatment options. *Consult Pharm.* 2013; 28: 110–21.
8. Gutierrez-Suarez R., Ruperto N., Gastaldi R. et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. *Arthritis Rheum.* 2006; 54: 2989–96.
9. Hahn B.H., McMahon M.A., Wilkinson A. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken).* 2012; 64: 797–808.
10. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997; 40: 1725.
11. Isenberg D.A., Rahman A., Allen E. et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford).* 2005; 44: 902–6.
12. Klein-Gitelman M.S. Pediatric Systemic Lupus Erythematosus. <http://www.medscape.com>. 2013. <http://emedicine.medscape.com/article/1008066-overview> (12 May 2013).
13. Merrill J.T., Neuwelt C.M., Wallace D.J. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum.* 2010; 62: 222–33.
14. Mosca M., Bencivelli W., Vitali C. et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. *Lupus.* 2000; 9: 445–50.
15. Rovin B.H., Furie R., Latinis K. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum.* 2012; 64: 1215–26.
16. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. *Arthritis Rheum.* 2007; 57: 1487–95.
17. Trachana M., Koutsonikoli A., Farmaki E. et al. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. *Rheumatol Int.* 2013; 33: 809–13.
18. Vitali C., Bencivelli W., Isenberg D.A. et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. *Clin Exp Rheumatol.* 1992; 10: 541–7.
19. Wallace D.J. Quality guidelines for systemic lupus erythematosus: slow but steady progress. *J Rheumatol.* 2013; 40: 542–3.
20. Wallace D.J., Hahn B.H., Elsevier. Dubois' lupus erythematosus and related syndromes. 8th ed. *Philadelphia, Elsevier. Saunders.* 2013.
21. van Vollenhoven RF, Mosca M, Bertias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis* 2014; 73:958.
22. Murdaca G, Orsi A, Spanò F, et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. *Autoimmun Rev* 2014; 13:75.